Literature DB >> 7720160

Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.

N Sato1, J M Brum, H Mitsumoto, G E DeBoer.   

Abstract

Two case reports have cited the recreational use of cocaine as possible trigger of a malignant hyperthermia (MH) crisis. We evaluated whether toxic concentrations of cocaine altered the in vitro muscle response to halothane during contracture tests for MH. Twenty-two patients were studied. Muscle biopsies were obtained and first tested for MH susceptibility with 3% halothane and caffeine contracture testing. Ten patients were diagnosed as MH-susceptible and 12 as MH non-susceptible, in accordance with the North American Malignant Hyperthermia Group protocol. Then, muscle strips were exposed to 1% halothane in the presence and absence of 0.1 mmol.L-1 cocaine. Cocaine alone did not affect baseline muscle tension in either group. With 1% halothane, MH non-susceptible muscle showed no contracture with or without cocaine. In contrast, in the presence of 1% halothane, MH-susceptible muscle showed either no change in contracture (six patients), an increase (two patients), or a decrease (two patients) when exposed to cocaine. However, the overall effect of cocaine on muscle contracture in the presence of 1% halothane was insignificant in both groups. We conclude that cocaine, even at toxic levels, does not have a direct effect on skeletal muscle contractility and thus is safe for MH-susceptible patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720160     DOI: 10.1007/BF03028270

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  22 in total

1.  Possible association of malignant hyperthermia with sevoflurane anesthesia.

Authors:  R Ochiai; Y Toyoda; I Nishio; J Takeda; H Sekiguchi; K Fukushima; E Kohda
Journal:  Anesth Analg       Date:  1992-04       Impact factor: 5.108

2.  Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.

Authors:  P J Adnet; R M Krivosic-Horber; G Haudecoeur; M M Adamantidis; G H Reyford; M Imbenotte; C Cordonnier
Journal:  Br J Anaesth       Date:  1990-12       Impact factor: 9.166

3.  Combined anesthetic- and stress-induced malignant hyperthermia in two offspring of malignant hyperthermic-susceptible parents.

Authors:  B A Britt
Journal:  Anesth Analg       Date:  1988-04       Impact factor: 5.108

4.  Malignant hyperpyrexia and isoflurane. A case report.

Authors:  D W Thomas; V J Dev; M J Whitehead
Journal:  Br J Anaesth       Date:  1987-09       Impact factor: 9.166

5.  Femoral block with mepivacaine for muscle biopsy in malignant hyperthermia patients.

Authors:  A Berkowitz; H Rosenberg
Journal:  Anesthesiology       Date:  1985-05       Impact factor: 7.892

6.  Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle.

Authors:  B A Britt; L Endrenyi; W Frodis; E Scott; W Kalow
Journal:  Can Anaesth Soc J       Date:  1980-01

7.  Action of local anesthetics on coupling systems in muscle.

Authors:  C P Bianchi; T C Bolton
Journal:  J Pharmacol Exp Ther       Date:  1967-08       Impact factor: 4.030

8.  Fatal malignant hyperthermia associated with recreational cocaine and ethanol abuse.

Authors:  F Loghmanee; M Tobak
Journal:  Am J Forensic Med Pathol       Date:  1986-09       Impact factor: 0.921

9.  Malignant hyperthermia during isoflurane anaesthesia.

Authors:  N McGuire; W R Easy
Journal:  Anaesthesia       Date:  1990-02       Impact factor: 6.955

10.  Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle.

Authors:  P J Adnet; R M Krivosic-Horber; G Haudecoeur; H G Reyford; M M Adamantidis; B A Dupuis
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

View more
  1 in total

1.  A rat model of spontaneous myopathy and malignant hyperthermia.

Authors:  L E Gonzalez; C V Meléndez-Vásquez; N A Gregson; S E File
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.